303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

Bibliographic Details
Main Authors: Hassane Zarour, John Kirkwood, Joe-Marc Chauvin, Arivarasan Karunamurthy, Douglas Hartman, Richelle DeBlasio, Quanquan Ding, Ornella Pagliano, Amy Rose
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items